DANISH BIO – DANSK BIOTEK organizes four major plenary meetings for our members throughout the year to increase our members' knowledge regarding specific biotech topics and to facilitate networking. The events usually take place in February, May, September and November.

We also organize approximately four "saloon" meetings annually. They are small, intimate, "meet the expert" meetings with typically 6-20 participants advocating more in-depth discussion and knowledge-sharing on specific themes.

News

<img width="300" height="69" class="logoImg animateRtGeneral" src="https://danskbiotek.dk/wp-content/uploads/2011/11/Expres2ionLogo_w_500px-300x69.png" />

ExpreS2ion announces completion of GLP safety study for ES2B-C001 (HER2-VLP) breast cancer vaccine candidate 16 April 2024

Hørsholm, Denmark, 16 April 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies... Read more

<img width="300" height="81" class="logoImg animateRtGeneral" src="https://danskbiotek.dk/wp-content/uploads/2023/07/zevra_inline_fullcolor_rgb_6in@72ppi-300x81.png" />

Zevra Therapeutics Presents New Data On The Long-Term Safety And Efficacy Of Arimoclomol As A Treatment For Niemann-Pick Disease Type C At The SIMD 45th Annual Meeting 15 April 2024

ELEBRATION, Fla., April 15, 2024 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA)... Read more

Great news from NMD Pharma! 22 March 2024

On 21 March 2024, the company released the great news about the peer-reviewed publication in the journal... Read more

Nyheder

GOOD NEWS: The EU Commission promotes investments in infrastructure and know-how 22 March 2024

The EU Commision has published the initiative: ”Building the future with nature: Boosting Biotechnology... Read more

dsm-firmenich and Zerion Pharma form a partnership to develop improved cannabinoids 15 February 2024

First Cannabidiol drug formulation from partnership to enter clinical studies in 2024 February 15, 2024... Read more

<img width="250" height="77" class="logoImg animateRtGeneral" src="https://danskbiotek.dk/wp-content/uploads/2024/01/Curasight-logo.jpg" />

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company 13 February 2024

Coming Phase I/IIa basket trial planned to include five select cancer indications Study will apply Curasight’s... Read more

<img width="250" height="77" class="logoImg animateRtGeneral" src="https://danskbiotek.dk/wp-content/uploads/2024/01/Curasight-logo.jpg" />

Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy 13 February 2024

Copenhagen, Denmark, 13 February 2024 – Curasight A/S (“Curasight” or the “Company”... Read more

<img width="300" height="69" class="logoImg animateRtGeneral" src="https://danskbiotek.dk/wp-content/uploads/2011/11/Expres2ionLogo_w_500px-300x69.png" />

ExpreS2ion announces financial results for the fourth quarter and full-year 2023 08 February 2024

Hørsholm, Denmark, 8 February 2024 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces... Read more

<img width="300" height="81" class="logoImg animateRtGeneral" src="https://danskbiotek.dk/wp-content/uploads/2023/07/zevra_inline_fullcolor_rgb_6in@72ppi-300x81.png" />

https://investors.zevra.com/news-releases/news-release-details/zevra-therapeutics-present-oppenheimer-34th-annual-healthcare 07 February 2024

CELEBRATION, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra... Read more

Copyright 2024 DANISH BIO – DANSK BIOTEK. All rights reserved.

created by: Mastafu Design